T1	SectionAnnotate 428 454	History of Present Illness
T2	SectionAnnotate 1932 2001	present review of systems was reviewed and notable for the following:
T3	SectionAnnotate 2692 2713	Past Medical History:
T4	SectionSkip 2871 3487	Medications the patient states to be taking prior to today's encounter.   Medication Sig    acetaminophen (TYLENOL) 500 mg tablet Take 1,000 mg by mouth daily as needed for Pain    ibuprofen (ADVIL,MOTRIN) 200 mg tablet Take 200 mg by mouth daily as needed for Pain    lipase-protease-amylase 5,000-17,000- 24,000 unit CAPDREC Take 1 capsule by mouth 3 (three) times daily with meals    metFORMIN (GLUCOPHAGE) 500 mg tablet Take 500 mg by mouth daily    ondansetron (ZOFRAN) 8 mg tablet Take 8 mg by mouth every 8 (eight) hours as needed for Nausea    simvastatin (ZOCOR) 40 mg tablet Take 40 mg by mouth daily
T5	SectionAnnotate 3549 3564	FAMILY HISTORY:
T6	SectionAnnotate 3566 3580	Family History
T7	SectionAnnotate 3835 3862	PERSONAL AND SOCIAL HISTORY
T8	SectionAnnotate 3864 3878	Social History
T9	SectionAnnotate 4352 4376	Social History Narrative
T10	SectionSkip 4874 5666	PHYSICAL EXAM via video observation:   Vitals: Not performed as today's visit was conducted via video  Constitutional: Normal appearance. No acute distress. Not ill-appearing. Not diaphoretic.  Head: Normocephalic, atraumatic. External ears normal. Nose normal.    Eyes: Extraocular movements intact. Conjunctivae normal. No eye discharge. No scleral icterus.  Neck: Normal range of motion.   Pulmonary/Chest: Normal effort. No respiratory distress. No cough.  GI: No abdominal distention.   Musculoskeletal: No apparent edema.   Skin: Not jaundiced. Not pale. No visible erythema. No visible rash.  Neurological: Alert and oriented to person, place and time. Able to stand from sitting and walk.   Psychiatric: Normal mood and affect. Behavior is normal. Judgment and thought content normal.
T11	SectionSkip 5671 5951	Relevant Diagnostic Studies:    Lab results: I personally reviewed and interpreted each of the patient's relevant lab tests as outlined     03/30/21  Na 130  K 3.8   Cl 
 92  Cr 0.92  AST 28  ALT 29  Tbili 1.0  Alk phos 67    WBC 8.8  Hgb 14.4  Plt 286    03/29/21: CA 19-9: 13737
T13	SectionSkip 6611 8119	FINDINGS *****:   5 mm right lower lobe nodule (image 16) is unchanged. There is a 2.8x 4.2 cm pancreatic neck hypodense mass with associated upstream pancreatic atrophy and pancreatic ductal dilatation.     This mass encompasses the superior mesenteric vein and main portal vein by <180 degrees. There is secondary moderate narrowing of these vessels which remain patent.      This mass encompasses the splenic vein near the confluence of the SMV by <180 degrees. There is severe secondary narrowing with the splenic vein remaining thinly patent.     This mass completely encompasses the gastroduodenal artery which remains fully patent.     The common and proper hepatic arteries are remote and from tumor. Superior mesenteric artery is also remote from tumor.     Hepatic steatosis. There is a 1.3 cm peripherally enhancing anterior right hepatic lobe lesion (image 57). There are additional subtle peripherally enhancing inferior right hepatic lobe lesions including a 7 mm lesion (image 74) and 5 mm lesion (image 70).     Bilateral adrenal thickening. The gallbladder and spleen are unremarkable.     The kidneys show symmetric enhancement. There is no hydronephrosis. No suspicious renal 
 mass.     Visualized loops of small and large bowel are not dilated. No suspicious abdominal nodes.     Aortic atherosclerosis. Normal abdominal aortic diameter (<3cm).      03/28/21  CT Chest  Normal chest CT.     Abdominal findings noted incidentally on described above, including ill-defined pancreatic mass.
T14	SectionSkip 8127 8161	Pathology:    03/19/21 EUS FNA/FNB
T15	SectionSkip 8163 8306	FINAL PATHOLOGIC DIAGNOSIS   PANCREAS, BODY, MASS, FINE NEEDLE BIOPSY:   -   RARE ATYPICAL GLANDS (SEE COMMENT).       Genomics  Pending STRATA
T16	SectionAnnotate 8310 8341	Impression and Recommendations:
T17	PROBLEM 306 327	his pancreatic cancer
T18	PROBLEM 483 497	abdominal pain
T19	PROBLEM 504 520	35lb weight loss
T20	PROBLEM 526 532	emesis
T21	TREATMENT 611 621	omeprazole
T22	TEST 649 652	EGD
T23	TEST 678 680	CT
T24	PROBLEM 685 709	Pancreatic cystic lesion
T25	PROBLEM 727 746	suspicious features
T26	PROBLEM 748 800	Additional 1 cm cystic lesion in the pancreatic body
T27	PROBLEM 813 835	the larger cystic mass
T28	TREATMENT 862 880	further management
T29	PROBLEM 891 910	Left adrenal nodule
T30	PROBLEM 918 944	retroperitoneal lymph node
T31	TEST 956 963	EGD/EUS
T32	PROBLEM 965 997	38mm mass in the pancreatic body
T33	PROBLEM 999 1014	lymphadenopathy
T34	TEST 1079 1081	CT
T35	PROBLEM 1089 1136	a 3.7cm ill defined low density pancreatic mass
T36	PROBLEM 1141 1209	1.4cm hypoattenuating liver mass in the inferior anterior right lobe
T37	TREATMENT 1258 1265	surgery
T38	TEST 1286 1302	CT panc protocol
T39	PROBLEM 1321 1350	borderline resectable disease
T40	TEST 1363 1368	CT AP
T41	PROBLEM 1370 1400	2.8x4.2cm pancreatic neck mass
T42	PROBLEM 1406 1419	PD dilatation
T43	TEST 1440 1443	MPV
T44	PROBLEM 1570 1597	1.3cm R hepatic lobe lesion
T45	PROBLEM 1602 1678	additional subtle peripherally enhancing inferior right hepatic lobe lesions
T46	TREATMENT 1802 1813	mFOLFIRINOX
T47	TREATMENT 1900 1915	clinical trials
T48	PROBLEM 2005 2018	early satiety
T49	PROBLEM 2020 2026	nausea
T50	PROBLEM 2042 2058	loss of appetite
T51	PROBLEM 2070 2081	weight loss
T52	PROBLEM 2104 2115	constipated
T53	TREATMENT 2134 2148	stool softener
T54	TEST 2156 2161	CT AP
T55	PROBLEM 2169 2188	biliary obstruction
T56	TEST 2213 2224	repeat labs
T57	PROBLEM 2240 2257	yellowing of eyes
T58	PROBLEM 2324 2339	itching of skin
T59	PROBLEM 2494 2510	prostate, breast
T60	PROBLEM 2512 2522	stomach ca
T61	PROBLEM 2524 2532	leukemia
T62	PROBLEM 2564 2580	a BRCA2 mutation
T63	TEST 2611 2635	a full review of systems
T64	PROBLEM 2735 2758	Borderline hypertension
T65	PROBLEM 2764 2772	Diabetes
T66	TREATMENT 2801 2810	metformin
T67	TREATMENT 2871 2882	Medications
T68	TREATMENT 2945 2955	Medication
T69	TREATMENT 2964 2987	acetaminophen (TYLENOL)
T70	PROBLEM 3045 3049	Pain
T71	TREATMENT 3054 3078	ibuprofen (ADVIL,MOTRIN)
T72	PROBLEM 3134 3138	Pain
T73	TREATMENT 3143 3158	lipase-protease
T74	TREATMENT 3159 3166	amylase
T75	TREATMENT 3262 3284	metFORMIN (GLUCOPHAGE)
T76	TREATMENT 3330 3350	ondansetron (ZOFRAN)
T77	PROBLEM 3418 3424	Nausea
T78	TREATMENT 3429 3448	simvastatin (ZOCOR)
T79	PROBLEM 3528 3543	Known Allergies
T80	PROBLEM 3622 3635	Breast cancer
T81	PROBLEM 3649 3664	Prostate cancer
T82	PROBLEM 3678 3692	Stomach cancer
T83	PROBLEM 3714 3722	Leukemia
T84	PROBLEM 3735 3750	Prostate cancer
T85	ClinicalCondition 3780 3808	hereditary pattern of cancer
T86	PROBLEM 5015 5029	acute distress
T87	PROBLEM 5054 5065	diaphoretic
T88	PROBLEM 5089 5099	atraumatic
T89	PROBLEM 5199 5212	eye discharge
T90	PROBLEM 5217 5232	scleral icterus
T91	PROBLEM 5302 5322	respiratory distress
T92	PROBLEM 5327 5332	cough
T93	PROBLEM 5342 5362	abdominal distention
T94	PROBLEM 5386 5400	apparent edema
T95	PROBLEM 5414 5423	jaundiced
T96	PROBLEM 5429 5433	pale
T97	PROBLEM 5438 5454	visible erythema
T98	PROBLEM 5459 5471	visible rash
T99	TEST 5821 5823	Na
T100	TEST 5829 5830	K
T101	TEST 5837 5839	Cl
T102	TEST 5846 5848	Cr
T103	TEST 5855 5858	AST
T104	TEST 5863 5866	ALT
T105	TEST 5871 5876	Tbili
T106	TEST 5882 5890	Alk phos
T107	TEST 5897 5900	WBC
T108	TEST 5906 5909	Hgb
T109	TEST 5916 5919	Plt
T110	TEST 5937 5939	CA
T111	TEST 6012 6050	the patient's relevant imaging studies
T112	TEST 6146 6148	CT
T113	TEST 6149 6198	AP (*****)  CT PANCREAS WITHOUT AND WITH CONTRAST
T114	PROBLEM 6251 6273	pancreatic neck cancer
T115	PROBLEM 6288 6308	vascular involvement
T116	TEST 6339 6363	CT images of the abdomen
T117	TEST 6433 6481	Multiphasic post-contrast images of the pancreas
T118	TEST 6496 6500	CTDI
T119	TEST 6532 6535	DLP
T120	TEST 6587 6589	CT
T121	PROBLEM 6629 6657	5 mm right lower lobe nodule
T122	PROBLEM 6692 6736	a 2.8x 4.2 cm pancreatic neck hypodense mass
T123	PROBLEM 6742 6780	associated upstream pancreatic atrophy
T124	PROBLEM 6785 6813	pancreatic ductal dilatation
T125	PROBLEM 6819 6828	This mass
T126	PROBLEM 6917 6962	secondary moderate narrowing of these vessels
T127	PROBLEM 6989 6998	This mass
T128	PROBLEM 7085 7111	severe secondary narrowing
T129	PROBLEM 7163 7172	This mass
T130	PROBLEM 7313 7318	tumor
T131	PROBLEM 7367 7372	tumor
T132	PROBLEM 7378 7395	Hepatic steatosis
T133	PROBLEM 7406 7472	a 1.3 cm peripherally enhancing anterior right hepatic lobe lesion
T134	PROBLEM 7495 7571	additional subtle peripherally enhancing inferior right hepatic lobe lesions
T135	PROBLEM 7582 7595	a 7 mm lesion
T136	PROBLEM 7611 7622	5 mm lesion
T137	PROBLEM 7639 7667	Bilateral adrenal thickening
T138	PROBLEM 7770 7784	hydronephrosis
T139	PROBLEM 7789 7812	suspicious renal 
 mass
T140	PROBLEM 7868 7875	dilated
T141	PROBLEM 7880 7906	suspicious abdominal nodes
T142	PROBLEM 7912 7934	Aortic atherosclerosis
T143	TEST 7992 7994	CT
T144	TEST 8023 8041	Abdominal findings
T145	PROBLEM 8091 8118	ill-defined pancreatic mass
T146	TEST 8127 8136	Pathology
T147	TEST 8150 8157	EUS FNA
T148	TEST 8214 8232	FINE NEEDLE BIOPSY
T149	PROBLEM 8388 8432	newly diagnosed metastatic pancreatic cancer
T150	TEST 8494 8505	his imaging
T151	TEST 8507 8516	pathology
T152	TEST 8522 8537	staging studies
T153	TREATMENT 8578 8587	treatment
T154	TREATMENT 8606 8622	systemic therapy
T155	TREATMENT 8636 8659	locoregional approaches
T156	TREATMENT 8669 8676	surgery
T157	TREATMENT 8680 8689	radiation
T158	TREATMENT 8834 8843	treatment
T159	TREATMENT 8909 8929	chemotherapy options
T160	PROBLEM 8934 8962	metastatic pancreatic cancer
T161	TREATMENT 8983 8990	therapy
T162	PROBLEM 9041 9061	co-morbid conditions
T163	TREATMENT 9123 9143	front-line treatment
T164	TEST 9154 9168	phase III data
T165	TREATMENT 9178 9209	FOLFIRINOX (biweekly infusional
T166	TREATMENT 9216 9226	leucovorin
T167	TREATMENT 9228 9238	irinotecan
T168	TREATMENT 9244 9255	oxaliplatin
T169	TREATMENT 9280 9291	gemcitabine
T170	TREATMENT 9297 9311	nab-paclitaxel
T171	TREATMENT 9351 9361	FOLFIRINOX
T172	TREATMENT 9403 9414	care option
T173	PROBLEM 9533 9561	Metastatic Pancreatic Cancer
T174	TEST 9621 9631	this study
T175	TREATMENT 9864 9885	Alternative treatment
T176	PROBLEM 9889 9910	the patient's disease
T177	TREATMENT 10050 10069	this clinical trial
T178	TreatmentType 10264 10277	birth control
T179	TREATMENT 10537 10562	the prohibited medication
T180	TREATMENT 10707 10717	medication
T181	PROBLEM 10770 10778	Jaundice
T182	TEST 10790 10795	CT AP
T183	PROBLEM 10835 10847	Cancer stage
T184	PROBLEM 10862 10868	Cancer
T185	PROBLEM 10878 10895	Pancreatic cancer
T186	PROBLEM 11015 11028	Stage IV (cT2
T187	TREATMENT 11432 11453	any billed procedures
T188	TEST 11591 11596	tests
T189	TEST 11801 11816	this evaluation
T190	TEST 11992 12007	this evaluation
T191	TEST 12014 12030	telehealth tools
T192	Datetime 459 467	03/16/21
T193	Symptom 483 497	abdominal pain
A1	IsPresentOnFirstCancerDiagnosis T193 yes
A2	IsCausedByDiagnosedCancer T193 yes
A3	ChronicVal T193 non-chronic
T194	Duration 499 502	1mo
R1	Temporal Arg1:T194 Arg2:T193	
T195	Symptom 504 521	35lb weight loss,
A4	IsPresentOnFirstCancerDiagnosis T195 yes
A5	IsCausedByDiagnosedCancer T195 yes
A6	ChronicVal T195 non-chronic
T196	Symptom 526 532	emesis
A7	IsPresentOnFirstCancerDiagnosis T196 yes
A8	IsCausedByDiagnosedCancer T196 yes
A9	ChronicVal T196 non-chronic
R2	HappensBefore Arg1:T193 Arg2:T192	
R3	HappensBefore Arg1:T195 Arg2:T192	
R4	HappensBefore Arg1:T196 Arg2:T192	
T197	Datetime 668 676	03/16/21
T198	Radiology 678 683	CT AP
A10	IntentVal T198 diagnosis
T199	RadPathResult 696 709;710 718;719 747	cystic lesion >/= 3 cm without suspicious features.
A11	RadPathResultVal T199 NoDisease
T200	Site 685 695	Pancreatic
R5	SiteOf Arg1:T200 Arg2:T199	
R6	ResultOfTest Desc:T199 Test:T198	
R7	TestOrProcedureConductedForProblem Test:T198 Prob:T193	
R8	TestOrProcedureConductedForProblem Test:T198 Prob:T195	
R9	TestOrProcedureConductedForProblem Test:T198 Prob:T196	
T201	RadPathResult 759 777	1 cm cystic lesion
A12	RadPathResultVal T201 NoDisease
T202	Site 785 835	pancreatic body inferior to the larger cystic mass
R10	SiteOf Arg1:T202 Arg2:T201	
R11	ResultOfTest Desc:T201 Test:T198	
T203	Datetime 946 954	03/19/21
R12	HappensAtOnDuring Arg1:T198 Arg2:T197	
T204	ProcedureName 956 963	EGD/EUS
A13	IntentVal T204 diagnosis
A14	TreatmentTypeVal T204 others
A15	TreatmentCategory T204 Others
T205	ClinicalCondition 970 974	mass
A16	RadPathResultVal T205 InitialCancerDiagnosis
T206	ClinicalCondition 999 1014	lymphadenopathy
A17	RadPathResultVal T206 InitialCancerDiagnosis
T207	Size 965 969	38mm
R13	SizeOf Arg1:T207 Arg2:T205	
T208	Site 982 997	pancreatic body
R14	SiteOf Arg1:T208 Arg2:T205	
T209	Site 1024 1035	body region
R15	SiteOf Arg1:T209 Arg2:T206	
A18	ContinuityVal T205 new
A19	ContinuityVal T206 new
R16	TestOrProcedureReveals Test:T204 Desc:T205	
R17	TestOrProcedureReveals Test:T204 Desc:T206	
R18	HappensAtOnDuring Arg1:T204 Arg2:T203	
T210	GenomicTest 1053 1067	Strata pending
A20	NegationModalityVal T210 planned_in_future
A21	GenomicTestType T210 Somatic
T211	Datetime 1213 1221	03/29/21
T212	DiagnosticLabTest 1223 1230	CA 19-9
A22	IntentVal T212 diagnosis
T213	LabTestResult 1232 1238	13,737
A23	LabTestResultVal T213 abnormal
R19	ResultOfTest Desc:T213 Test:T212	
R20	HappensAtOnDuring Arg1:T212 Arg2:T211	
T214	Datetime 1069 1077	03/28/21
T215	Radiology 1079 1087	CT Chest
A24	IntentVal T215 staging
T216	RadPathResult 1097 1120;1132 1136	ill defined low density mass
A25	RadPathResultVal T216 InitialCancerDiagnosis
T217	RadPathResult 1147 1162;1169 1173	hypoattenuating mass
A26	RadPathResultVal T217 InitialCancerDiagnosis
T218	Site 1121 1131	pancreatic
R21	SiteOf Arg1:T218 Arg2:T216	
T219	Size 1091 1096	3.7cm
A27	HistoryVal T219 new
A28	EpisodeDescription T219 FirstOccurrence
R22	SizeOf Arg1:T219 Arg2:T216	
T220	Size 1141 1146	1.4cm
A29	HistoryVal T220 new
A30	EpisodeDescription T220 FirstOccurrence
T221	Site 1163 1168	liver
T222	Laterality 1181 1209	inferior anterior right lobe
R24	LateralityOfSite Arg1:T222 Arg2:T221	
R25	SiteOf Arg1:T221 Arg2:T217	
R26	ResultOfTest Desc:T216 Test:T215	
R27	ResultOfTest Desc:T217 Test:T215	
R28	HappensAtOnDuring Arg1:T215 Arg2:T214	
T223	Radiology 1286 1302	CT panc protocol
A31	NegationModalityVal T223 hypothetical_in_future
A32	IntentVal T223 staging
T224	ProcedureName 1304 1317	potential trt
A33	NegationModalityVal T224 hypothetical_in_future
A34	IntentVal T224 treatment-curative
A35	TreatmentTypeVal T224 local
A36	TreatmentCategory T224 AntiNeoPlastics
T225	Datetime 1240 1248	03/29/21
R29	HappensAfter Arg1:T225 Arg2:T223	
R30	HappensAfter Arg1:T225 Arg2:T224	
T226	DiseaseState 1321 1350	borderline resectable disease
A37	NegationModalityVal T226 uncertain_in_present
T227	Datetime 1353 1361	04/01/21
T228	Radiology 1363 1368	CT AP
A38	IntentVal T228 staging
T229	Size 1370 1379	2.8x4.2cm
A39	HistoryVal T229 new
A40	EpisodeDescription T229 FirstOccurrence
T231	Site 1380 1395	pancreatic neck
R34	HappensAtOnDuring Arg1:T228 Arg2:T227	
T232	RadPathResult 1591 1597	lesion
A42	RadPathResultVal T232 InitialCancerDiagnosis
T233	Site 1578 1590	hepatic lobe
T234	Laterality 1576 1577	R
R35	LateralityOfSite Arg1:T234 Arg2:T233	
R36	SiteOf Arg1:T233 Arg2:T232	
T235	Size 1570 1575	1.3cm
A43	HistoryVal T235 new
A44	EpisodeDescription T235 FirstOccurrence
R37	SizeOf Arg1:T235 Arg2:T232	
R38	ResultOfTest Desc:T232 Test:T228	
T236	RadPathResult 1602 1642;1671 1678	additional subtle peripherally enhancing lesions
A45	RadPathResultVal T236 InitialCancerDiagnosis
T237	Site 1658 1670	hepatic lobe
T238	Laterality 1643 1657	inferior right
R39	LateralityOfSite Arg1:T238 Arg2:T237	
R40	SiteOf Arg1:T237 Arg2:T236	
R41	SiteOf Arg1:T237 Arg2:T236	
R42	ResultOfTest Desc:T236 Test:T228	
T239	Size 1680 1691	7mm and 5mm
A46	HistoryVal T239 new
A47	EpisodeDescription T239 FirstOccurrence
R43	SizeOf Arg1:T239 Arg2:T236	
T240	ClinicalTrial 1758 1781	Precision Promise trial
A48	NegationModalityVal T240 hypothetical_in_future
T241	MedicationRegimen 1802 1813	mFOLFIRINOX
A49	NegationModalityVal T241 hypothetical_in_future
T242	Datetime 1696 1704	04/03/21
R44	HappensAfter Arg1:T240 Arg2:T242	
R45	HappensAfter Arg1:T241 Arg2:T242	
T243	Symptom 2005 2018	early satiety
A50	IsPresentOnFirstCancerDiagnosis T243 yes
A51	IsCausedByDiagnosedCancer T243 yes
A52	ChronicVal T243 non-chronic
T244	Symptom 2020 2026;2027 2040	nausea post prandial
A53	IsPresentOnFirstCancerDiagnosis T244 yes
A54	IsCausedByDiagnosedCancer T244 yes
A55	ChronicVal T244 non-chronic
T245	Symptom 2070 2081;2092 2096	weight loss 35lb
A56	IsPresentOnFirstCancerDiagnosis T245 yes
A57	IsCausedByDiagnosedCancer T245 yes
A58	ChronicVal T245 non-chronic
T246	Symptom 2042 2058	loss of appetite
A59	IsPresentOnFirstCancerDiagnosis T246 yes
A60	IsCausedByDiagnosedCancer T246 yes
A61	ChronicVal T246 non-chronic
T247	Symptom 2104 2115	constipated
A62	IsPresentOnFirstCancerDiagnosis T247 no
A63	IsCausedByDiagnosedCancer T247 yes
A64	ChronicVal T247 non-chronic
T248	MedicationRegimen 2134 2148	stool softener
A65	TreatmentContinuityVal T248 continuing
A66	TreatmentTypeVal T248 others
R46	TreatmentAdministeredForProblem Treatment:T248 Prob:T247	
T249	Radiology 2156 2161	CT AP
A67	NegationModalityVal T249 planned_in_future
A68	IntentVal T249 others
T250	ClinicalCondition 2169 2188	biliary obstruction
A69	NegationModalityVal T250 uncertain_in_present
R47	TestOrProcedureConductedForProblem Test:T249 Prob:T250	
T251	Symptom 2240 2257	yellowing of eyes
A70	IsPresentOnFirstCancerDiagnosis T251 no
A71	IsCausedByDiagnosedCancer T251 yes
A72	ChronicVal T251 non-chronic
T252	Duration 2265 2279	past two weeks
R48	HappensAtOnDuring Arg1:T251 Arg2:T252	
T253	PhysicalActivity 2283 2295	energy is ok
T254	Symptom 2324 2339	itching of skin
A73	NegationModalityVal T254 negated
T255	Symptom 2353 2379	lower back started hurting
A74	IsPresentOnFirstCancerDiagnosis T255 no
A75	IsCausedByDiagnosedCancer T255 yes
A76	ChronicVal T255 non-chronic
T256	ClinicalCondition 2494 2502;2520 2522	prostate ca
A77	ExperiencerVal T256 family
T257	ClinicalCondition 2504 2510;2520 2522	breast ca
A78	ExperiencerVal T257 family
T258	ClinicalCondition 2512 2519;2520 2522	stomach ca
A79	ExperiencerVal T258 family
T259	ClinicalCondition 2524 2532	leukemia
A80	ExperiencerVal T259 family
T260	GenomicTestResult 2566 2580	BRCA2 mutation
A81	ExperiencerVal T260 family
A82	GenomicTestType T260 Germline
T261	Datetime 2584 2588	2020
R49	HappensAtOnDuring Arg1:T260 Arg2:T261	
T262	SectionSkip 2871 3487	Medications the patient states to be taking prior to today's encounter.   Medication Sig    acetaminophen (TYLENOL) 500 mg tablet Take 1,000 mg by mouth daily as needed for Pain    ibuprofen (ADVIL,MOTRIN) 200 mg tablet Take 200 mg by mouth daily as needed for Pain    lipase-protease-amylase 5,000-17,000- 24,000 unit CAPDREC Take 1 capsule by mouth 3 (three) times daily with meals    metFORMIN (GLUCOPHAGE) 500 mg tablet Take 500 mg by mouth daily    ondansetron (ZOFRAN) 8 mg tablet Take 8 mg by mouth every 8 (eight) hours as needed for Nausea    simvastatin (ZOCOR) 40 mg tablet Take 40 mg by mouth daily
A83	SectionSkipType T262 medications
T263	SectionSkip 3496 3543	Allergies/Contraindications  No Known Allergies
A84	SectionSkipType T263 allergies
T264	ClinicalCondition 2735 2758	Borderline hypertension
A85	ChronicVal T264 chronic
A86	ContinuityVal T264 stable
T265	ClinicalCondition 2764 2772	Diabetes
A87	ChronicVal T265 chronic
A88	ContinuityVal T265 stable
T266	MedicationName 2801 2810	metformin
A89	TreatmentContinuityVal T266 continuing
A90	TreatmentTypeVal T266 others
R50	TreatmentAdministeredForProblem Treatment:T266 Prob:T265	
T267	ClinicalCondition 3735 3750	Prostate cancer
A91	ExperiencerVal T267 family
T268	Tobacco 4150 4162	Never Smoker
A92	NegationModalityVal T268 negated
T269	PerformanceStatus 4854 4855	0
A93	PerformanceStatusType T269 ECOG
T270	ClinicalCondition 3622 3635	Breast cancer
A94	ExperiencerVal T270 family
T271	ClinicalCondition 3649 3664	Prostate cancer
A95	ExperiencerVal T271 family
T272	ClinicalCondition 3678 3692	Stomach cancer
A96	ExperiencerVal T272 family
T273	ClinicalCondition 3714 3722	Leukemia
A97	ExperiencerVal T273 family
T274	Age 8370 8377	52 y.o.
T275	ClinicalCondition 8415 8433	pancreatic cancer.
T276	Metastasis 8404 8414	metastatic
A98	EpisodeDescription T276 FirstOccurrence
R51	TumorDesc TumorDetails:T276 Desc:T275	
T277	TreatmentType 8606 8622	systemic therapy
A99	TreatmentContinuityVal T277 planned
A100	TreatmentTypeVal T277 maintenance
T278	TreatmentType 9123 9143	front-line treatment
A101	TreatmentContinuityVal T278 planned
A102	TreatmentTypeVal T278 maintenance
T279	MedicationRegimen 9178 9188	FOLFIRINOX
A104	TreatmentTypeVal T279 maintenance
T280	MedicationName 9199 9214	infusional 5-FU
A105	TreatmentContinuityVal T280 planned
A106	TreatmentTypeVal T280 maintenance
T281	MedicationName 9216 9226	leucovorin
A107	TreatmentContinuityVal T281 planned
A108	TreatmentTypeVal T281 maintenance
A109	TreatmentIntentVal T281 palliative
A110	TreatmentCategory T281 AntiNeoPlastics
A111	TreatmentIntentVal T280 palliative
A112	TreatmentCategory T280 AntiNeoPlastics
A113	TreatmentIntentVal T279 palliative
A114	TreatmentIntentVal T278 palliative
A115	TreatmentIntentVal T277 palliative
T282	MedicationName 9228 9238	irinotecan
A116	TreatmentContinuityVal T282 planned
A117	TreatmentTypeVal T282 maintenance
A118	TreatmentIntentVal T282 palliative
A119	TreatmentCategory T282 AntiNeoPlastics
T283	MedicationName 9244 9255	oxaliplatin
A120	TreatmentContinuityVal T283 planned
A121	TreatmentTypeVal T283 maintenance
A122	TreatmentIntentVal T283 palliative
A123	TreatmentCategory T283 AntiNeoPlastics
T284	Frequency 9190 9198	biweekly
R52	Temporal Arg1:T284 Arg2:T279	
T285	MedicationRegimen 9280 9311	gemcitabine plus nab-paclitaxel
A124	NegationModalityVal T285 hypothetical_in_future
A125	TreatmentContinuityVal T285 planned
A126	TreatmentTypeVal T285 maintenance
A127	TreatmentIntentVal T285 palliative
A103	NegationModalityVal T279 hypothetical_in_future
A128	NegationModalityVal T280 hypothetical_in_future
A129	NegationModalityVal T281 hypothetical_in_future
A130	NegationModalityVal T282 hypothetical_in_future
A131	NegationModalityVal T283 hypothetical_in_future
T286	MedicationRegimen 9351 9361	FOLFIRINOX
A132	NegationModalityVal T286 planned_in_future
A133	TreatmentContinuityVal T286 planned
A134	TreatmentTypeVal T286 maintenance
A135	TreatmentIntentVal T286 palliative
T287	Symptom 10770 10778	Jaundice
A136	IsPresentOnFirstCancerDiagnosis T287 no
A137	IsCausedByDiagnosedCancer T287 yes
A138	ChronicVal T287 non-chronic
T288	Radiology 10790 10795	CT AP
A139	NegationModalityVal T288 planned_in_future
A140	IntentVal T288 diagnosis
R53	TestOrProcedureConductedForProblem Test:T288 Prob:T287	
T289	Stage 11021 11023	IV
A141	EpisodeDescription T289 FirstOccurrence
T290	ClinicalCondition 10878 10895	Pancreatic cancer
T291	Metastasis 10896 10908	metastasized
A142	EpisodeDescription T291 FirstOccurrence
T292	Site 10912 10917	liver
R54	SiteOf Arg1:T292 Arg2:T291	
R55	TumorDesc TumorDetails:T291 Desc:T290	
R56	TumorDesc TumorDetails:T289 Desc:T290	
T293	ClinicalTrial 9496 9528	Precision Promise Platform Trial
A143	NegationModalityVal T293 hypothetical_in_future
T294	Metastasis 9533 9543	Metastatic
A144	EpisodeDescription T294 FirstOccurrence
T295	ClinicalCondition 9544 9561	Pancreatic Cancer
R57	TumorDesc TumorDetails:T294 Desc:T295	
R58	InclusionCriteriaFor Arg1:T295 Arg2:T293	
T296	SectionSkip 4874 5666	PHYSICAL EXAM via video observation:   Vitals: Not performed as today's visit was conducted via video  Constitutional: Normal appearance. No acute distress. Not ill-appearing. Not diaphoretic.  Head: Normocephalic, atraumatic. External ears normal. Nose normal.    Eyes: Extraocular movements intact. Conjunctivae normal. No eye discharge. No scleral icterus.  Neck: Normal range of motion.   Pulmonary/Chest: Normal effort. No respiratory distress. No cough.  GI: No abdominal distention.   Musculoskeletal: No apparent edema.   Skin: Not jaundiced. Not pale. No visible erythema. No visible rash.  Neurological: Alert and oriented to person, place and time. Able to stand from sitting and walk.   Psychiatric: Normal mood and affect. Behavior is normal. Judgment and thought content normal.
T297	SectionSkip 5671 5839;5842 5951	Relevant Diagnostic Studies:    Lab results: I personally reviewed and interpreted each of the patient's relevant lab tests as outlined     03/30/21  Na 130  K 3.8   Cl 92  Cr 0.92  AST 28  ALT 29  Tbili 1.0  Alk phos 67    WBC 8.8  Hgb 14.4  Plt 286    03/29/21: CA 19-9: 13737
A145	SectionSkipType T297 laboratory
T298	SectionSkip 5955 7805;7808 8118	Radiology: I personally reviewed and interpreted each of the patient's relevant imaging studies in conjunction with the corresponding formal radiology reports, as outlined in HPI    03/29/21 CT AP (*****)  CT PANCREAS WITHOUT AND WITH CONTRAST     ***** HISTORY *****:   52 years old, history of pancreatic neck cancer. Evaluate for vascular involvement.     ***** TECHNIQUE *****:   CT images of the abdomen acquired without and with 130 mL Omnipaque 300 intravenous contrast. Multiphasic post-contrast images of the pancreas acquired.     CTDI: 10.15,10.88,12.69,12.68 mGy   DLP: 278.61,10.88,339.05,338.71 mGy-cm     COMPARISON: CT 03/16/2021     ***** FINDINGS *****:   5 mm right lower lobe nodule (image 16) is unchanged. There is a 2.8x 4.2 cm pancreatic neck hypodense mass with associated upstream pancreatic atrophy and pancreatic ductal dilatation.     This mass encompasses the superior mesenteric vein and main portal vein by <180 degrees. There is secondary moderate narrowing of these vessels which remain patent.      This mass encompasses the splenic vein near the confluence of the SMV by <180 degrees. There is severe secondary narrowing with the splenic vein remaining thinly patent.     This mass completely encompasses the gastroduodenal artery which remains fully patent.     The common and proper hepatic arteries are remote and from tumor. Superior mesenteric artery is also remote from tumor.     Hepatic steatosis. There is a 1.3 cm peripherally enhancing anterior right hepatic lobe lesion (image 57). There are additional subtle peripherally enhancing inferior right hepatic lobe lesions including a 7 mm lesion (image 74) and 5 mm lesion (image 70).     Bilateral adrenal thickening. The gallbladder and spleen are unremarkable.     The kidneys show symmetric enhancement. There is no hydronephrosis. No suspicious renal mass.     Visualized loops of small and large bowel are not dilated. No suspicious abdominal nodes.     Aortic atherosclerosis. Normal abdominal aortic diameter (<3cm).      03/28/21  CT Chest  Normal chest CT.     Abdominal findings noted incidentally on described above, including ill-defined pancreatic mass
T299	SectionSkip 8127 8306	Pathology:    03/19/21 EUS FNA/FNB  FINAL PATHOLOGIC DIAGNOSIS   PANCREAS, BODY, MASS, FINE NEEDLE BIOPSY:   -   RARE ATYPICAL GLANDS (SEE COMMENT).       Genomics  Pending STRATA
R59	TestOrProcedureReveals Test:T204 Desc:T207	
R60	TestOrProcedureReveals Test:T215 Desc:T219	
R62	TestOrProcedureReveals Test:T215 Desc:T220	
R23	SizeOf Arg1:T220 Arg2:T217	
R61	TestOrProcedureReveals Test:T228 Desc:T229	
R63	TestOrProcedureReveals Test:T228 Desc:T239	
R64	TestOrProcedureReveals Test:T228 Desc:T235	
T300	Datetime 2784 2794	March 2021
R65	HappensAtOnDuring Arg1:T265 Arg2:T300	
T301	Employment 4380 4405	Works as a ***** in *****
A146	IsStoppedOrContinuing T301 continuing
T302	PatientCharacteristics 4413 4436	two twin 12yo daughters
T12	Datetime 10822 10827	today
R66	HappensAtOnDuring Arg1:T288 Arg2:T12	
T303	TNM 11025 11038	cT2, cN1, cM1
A147	EpisodeDescription T303 FirstOccurrence
R67	TumorDesc TumorDetails:T290 Desc:T303	
T304	ClinicalCondition 310 327	pancreatic cancer
A148	ChronicVal T304 non-chronic
T305	Datetime 581 593	January 2021
T306	ClinicalCondition 570 577	hpylori
A149	ChronicVal T306 chronic
R68	HappensOverlapping Arg1:T305 Arg2:T306	
T307	MedicationName 611 621	omeprazole
A150	TreatmentContinuityVal T307 unclear
A151	TreatmentTypeVal T307 others
A152	TreatmentIntentVal T307 others
A153	TreatmentCategory T307 Others
R69	TreatmentAdministeredForProblem Treatment:T307 Prob:T306	
T308	ProcedureName 649 657	EGD/colo
A154	IntentVal T308 others
A155	TreatmentTypeVal T308 others
A156	TreatmentCategory T308 Others
A157	NegationModalityVal T308 planned_in_future
R70	TestOrProcedureConductedForProblem Test:T308 Prob:T306	
T309	RadPathResult 824 835	cystic mass
A158	RadPathResultVal T309 NoDisease
R71	ResultOfTest Desc:T309 Test:T198	
T310	RadPathResult 904 910	nodule
A159	RadPathResultVal T310 Unclear
T311	Laterality 891 895	Left
T312	Site 896 903	adrenal
R72	LateralityOfSite Arg1:T311 Arg2:T312	
R73	SiteOf Arg1:T312 Arg2:T310	
T313	LymphNodeInvolvement 934 944	lymph node
A160	NegationModalityVal T313 uncertain_in_present
T314	Site 918 932	retroperitonea
R74	SiteOf Arg1:T314 Arg2:T313	
R75	ResultOfTest Desc:T310 Test:T198	
T315	RadPathResult 934 944	lymph node
A161	RadPathResultVal T315 Unclear
R76	ResultOfTest Desc:T315 Test:T198	
T316	ProcedureName 1037 1044	FNA/FNB
A162	IntentVal T316 diagnosis
R77	HappensAtOnDuring Arg1:T203 Arg2:T210	
R78	HappensAtOnDuring Arg1:T203 Arg2:T316	
T317	LocalInvasion 1321 1342	borderline resectable
A163	NegationModalityVal T317 uncertain_in_present
T230	RadPathResult 1396 1400	mass
A41	RadPathResultVal T230 InitialCancerDiagnosis
R31	SiteOf Arg1:T231 Arg2:T230	
R32	SizeOf Arg1:T229 Arg2:T230	
T318	RadPathResult 1406 1419	PD dilatation
A164	RadPathResultVal T318 Others
T319	LocalInvasion 1421 1431	compresses
A165	EpisodeDescription T319 FirstOccurrence
T320	LocalInvasion 1461 1472	encompasses
T321	Site 1473 1485	splenic vein
T322	Site 1432 1435	SMV
T323	Site 1440 1443	MPV
R33	SiteOf Arg1:T322 Arg2:T319	
R79	SiteOf Arg1:T323 Arg2:T319	
R80	SiteOf Arg1:T321 Arg2:T320	
T324	LocalInvasion 1531 1542	encompasses
A166	EpisodeDescription T324 FirstOccurrence
T325	Site 1543 1546	GDA
R81	SiteOf Arg1:T325 Arg2:T324	
R82	TestOrProcedureReveals Test:T228 Desc:T324	
R83	ResultOfTest Desc:T230 Test:T228	
R84	ResultOfTest Desc:T318 Test:T228	
R85	TestOrProcedureReveals Test:T228 Desc:T319	
R86	TestOrProcedureReveals Test:T228 Desc:T320	
T326	ClinicalTrial 1900 1915	clinical trials
A167	NegationModalityVal T326 hypothetical_in_future
A168	ContinuityVal T251 new
A169	NegationModalityVal T85 negated
A170	ExperiencerVal T85 family
T327	SDoH 3927 3934	Married
A171	IsStoppedOrContinuing T327 continuing
T328	Alcohol 4246 4251	Never
A172	NegationModalityVal T328 negated
T329	TreatmentType 8669 8676	surgery
A173	TreatmentTypeVal T329 local
A174	TreatmentIntentVal T329 palliative
A175	NegationModalityVal T329 hypothetical_in_future
T330	TreatmentType 8680 8689	radiation
A176	NegationModalityVal T330 hypothetical_in_future
A177	TreatmentTypeVal T330 local
A178	TreatmentIntentVal T330 palliative
T331	TreatmentType 8909 8929	chemotherapy options
A179	TreatmentContinuityVal T331 planned
A180	TreatmentTypeVal T331 maintenance
A181	TreatmentIntentVal T331 palliative
T332	ClinicalCondition 8945 8962	pancreatic cancer
A182	ChronicVal T332 non-chronic
T333	Metastasis 8934 8944	metastatic
R87	TumorDesc TumorDetails:T333 Desc:T332	
T334	PerformanceStatus 9021 9039	performance status
A183	PerformanceStatusType T334 Other
A184	NegationModalityVal T178 hypothetical_in_future
A185	TreatmentTypeVal T178 others
A186	TreatmentIntentVal T178 others
T335	Datetime 11003 11013	04/18/2021
R88	HappensAtOnDuring Arg1:T335 Arg2:T289	
R89	HappensAtOnDuring Arg1:T335 Arg2:T303	
T336	Datetime 11071 11081	04/18/2021
T337	Age 215 217	52
T338	ClinicalCondition 1343 1350	disease
A187	ChronicVal T338 non-chronic
R90	TestOrProcedureConductedForProblem Test:T224 Prob:T338	
T339	PatientCharacteristics 4413 4432	two twin ***** kids
T340	ap_start 8310 8320	Impression
T341	ap_end 11077 11081	2021
T342	hpi_end 1915 1916	.
T343	Datetime 79 89	12/24/1968
T344	Datetime 141 151	04/18/2021
T345	hpi_start 0 7	INITIAL
